Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy M Shefner

Showing results (71-80 of 105) with videos related to

Pageof 11
Sort By:
Human Molecular Genetics|December 3, 2005
Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit age-dependent neurological deficits and altered endosome traffickingShinji Hadano, Susanna C Benn, Shigeru Kakuta, et al.
The European Journal of Neuroscience|September 21, 2007
Genetic ablation of NMDA receptor subunit NR3B in mouse reveals motoneuronal and nonmotoneuronal phenotypesStephan Niemann, Hiroaki Kanki, Yasuyuki Fukui, et al.
Muscle & Nerve|June 2, 2021
Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patientsCarol Milligan, Nazem Atassi, Suma Babu, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 15, 2022
Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALSShiran Salomon-Zimri, Avital Pushett, Niva Russek-Blum, et al.
Journal of Medical Economics|March 17, 2023
Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving <i>reldesemtiv</i> or placebo in FORTITUDE-ALSPaulos Gebrehiwet, Lisa Meng, Stacy A Rudnicki, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 17, 2025
Pridopidine treatment in ALS: subgroup analyses from the HEALEY ALS Platform trialMichal Geva, Y Paul Goldberg, Melanie L Leitner, et al.
Nature Reviews. Neurology|December 19, 2020
Improving clinical trial outcomes in amyotrophic lateral sclerosisMatthew C Kiernan, Steve Vucic, Kevin Talbot, et al.
Muscle & Nerve|November 26, 2013
Electrical impedance myography correlates with standard measures of ALS severitySeward B Rutkove, James B Caress, Michael S Cartwright, et al.
The Lancet. Neurology|September 27, 2013
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trialMerit E Cudkowicz, Leonard H van den Berg, Jeremy M Shefner, et al.
Journal of Clinical Pharmacology|April 29, 2014
Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosisYanli Zhao, Merit E Cudkowicz, Jeremy M Shefner, et al.
Pageof 11

Showing results (71-80 of 105) with videos related to

Sort By:
Pageof 11
Human Molecular Genetics|December 3, 2005
Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit age-dependent neurological deficits and altered endosome traffickingShinji Hadano, Susanna C Benn, Shigeru Kakuta, et al.
The European Journal of Neuroscience|September 21, 2007
Genetic ablation of NMDA receptor subunit NR3B in mouse reveals motoneuronal and nonmotoneuronal phenotypesStephan Niemann, Hiroaki Kanki, Yasuyuki Fukui, et al.
Muscle & Nerve|June 2, 2021
Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patientsCarol Milligan, Nazem Atassi, Suma Babu, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 15, 2022
Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALSShiran Salomon-Zimri, Avital Pushett, Niva Russek-Blum, et al.
Journal of Medical Economics|March 17, 2023
Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving <i>reldesemtiv</i> or placebo in FORTITUDE-ALSPaulos Gebrehiwet, Lisa Meng, Stacy A Rudnicki, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 17, 2025
Pridopidine treatment in ALS: subgroup analyses from the HEALEY ALS Platform trialMichal Geva, Y Paul Goldberg, Melanie L Leitner, et al.
Nature Reviews. Neurology|December 19, 2020
Improving clinical trial outcomes in amyotrophic lateral sclerosisMatthew C Kiernan, Steve Vucic, Kevin Talbot, et al.
Muscle & Nerve|November 26, 2013
Electrical impedance myography correlates with standard measures of ALS severitySeward B Rutkove, James B Caress, Michael S Cartwright, et al.
The Lancet. Neurology|September 27, 2013
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trialMerit E Cudkowicz, Leonard H van den Berg, Jeremy M Shefner, et al.
Journal of Clinical Pharmacology|April 29, 2014
Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosisYanli Zhao, Merit E Cudkowicz, Jeremy M Shefner, et al.
Pageof 11